Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      iOnctura Announces First Patient Dosed in a Phase I Clinical Study of its Novel Highly Selective PI3Kδ Inhibitor, IOA-244 for Solid Tumours


      News provided by

      iOnctura

      Feb 26, 2020, 03:00 ET

      Share this article

      Share this article


      GENEVA, Feb. 26, 2020 /PRNewswire/ -- iOnctura SA., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces it has  dosed the first patient in a first-in-human dose escalation and expansion study evaluating the safety and preliminary efficacy of its lead programme IOA-244, which is being developed as a novel targeted therapy for solid tumours. 

      The phase I study will enrol approximately 60 patients with solid tumours that overexpress PI3Kδ and are burdened by immune cells of the suppressor phenotype that are sensitive to PI3Kδ inhibition. The dose escalation part of the study will evaluate the safety, tolerability and pharmacokinetic profile of IOA-244 and is being led by principal investigators Professor Evans from the Beatson West of Scotland Cancer Centre and University of Glasgow, and Professor Maio from the University Hospital of Siena. Results from the phase I study are expected in early 2021.

      Michael Lahn, Chief Medical Officer of iOnctura, commented: "Our mission is to achieve true precision medicine that optimally treats patients according to the root causes of their disease. The start of this trial represents an important milestone for iOnctura to clinically demonstrate that highly selective PI3Kδ inhibition not only drives an immune-mediated response but also a direct anti-tumoural effect in a stratified patient population across multiple solid tumour indications.  This study will generate important insights into IOA-244, and its potential to provide meaningful and lasting clinical benefit for patients with cancer. We are very pleased to collaborate with Professor Evans and Professor Maio on this significant first-in-human dose escalation study. We look forward to continuing our evolution into a leading biopharmaceutical company with a diverse and sustainable pipeline in cancer and fibrosis."

      Professor Maio, Department of Medical Oncology, University Hospital of Siena, Italy said: "We are excited to participate in iOnctura's first-in-human study. iOnctura's innovative and differentiated approach has the potential to offer new, advanced treatment options to cancer patients and we are looking forward to evaluating this promising and unique target."

      Commenting on the study, recently appointed Clinical Advisory Board member, Dr. Jordi Rodón Ahnert, Clinical co-director, MD Anderson Cancer Center, added: "The design of the clinical trial is novel because it is going to investigate patients with expected high PI3Kδ expression and immune suppression both of which are underlying causes of treatment resistance in many solid tumours. iOnctura's novel compound, IOA-244, could be critically important for the treatment of solid tumours that are burdened with an immune-suppressive tumour microenvironment."

      About IOA-244

      IOA-244 is a next generation PI3Kδ inhibitor with a unique chemical structure, exquisite selectivity, excellent drug-like properties and an expected best-in-class safety profile. It is being developed as a novel targeted therapy for solid tumours that over express PI3Kδ and are burdened by immune-suppressive subtypes sensitive to PI3Kδ inhibition.

      About iOnctura

      iOnctura SA, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin out from Merck. It is a clinical stage biopharmaceutical company developing a pipeline of next generation, differentiated molecules that are at the forefront of pioneering new therapies for the treatment of cancer. Each of iOnctura's programmes harness the combined effect of immune-mediated and direct anti-tumour activity and aim to deliver molecules with superior clinical efficacy and safety in oncology.

      The company's lead programme, IOA-244, entered the clinic in Q1 2020. The study is aimed to clinically demonstrate for the first time that a highly selective PI3Kδ inhibition not only drives an immune-mediated response but also a direct anti-tumoural effect in a stratified patient population across multiple solid tumour indications. The company's second molecule is a novel autotaxin (ATX) inhibitor at IND stage for patients with solid tumours burdened with cancer-associated fibrosis. For more information, please visit www.ionctura.com

      About the Beatson West of Scotland Cancer Centre, UK

      The Beatson West of Scotland Cancer Centre is the largest cancer centre in Scotland and serves a population of 2.6 million and has clinical links with all hospitals in the West of Scotland.

      The Beatson is renowned for being the lead centre for delivering non-surgical cancer care.

      There are approximately 150 innovative clinical trials ongoing at any one time, offering cutting-edge technologies, equipment and access to new cancer treatments. www.beatson.scot.nhs.uk

      Professor Jeff Evans

      Professor Jeff Evans is Professor of Translational Cancer Research and Clinical Lead of the Institute of Cancer Sciences, University of Glasgow. He is also Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre, and Lead of the Glasgow Experimental Cancer Medicine Centre (ECMC).  His clinical research interests are in clinical development of novel anti-cancer agents including molecular targeted therapies, immunotherapy, and advanced cellular therapies. He leads a multiple number of Phase I clinical trials of innovative anti-cancer agents, including the development of novel therapies for gastro-oesophageal and hepato-biliary-pancreatic cancers and melanoma.

      About University Hospital of Siena, Italy

      The University Hospital of Siena is a centre of reference for clinical research in the field of immune oncology. The centre is involved in some of the most important global immunotherapy trials in solid tumours, with the main purpose of making the latest therapeutic treatments available to patients.

      Since 2017, the University Hospital of Siena established a multidisciplinary entity, the Centre for Immuno-Oncology (CIO), allowing a complete and successful integration of clinical research services.

      The CIO has four integrated units, including the clinical facilities of Medical Oncology and Immunotherapy, the Clinical Research unit for clinical trials and the Translational and Pre-Clinical research laboratories. www.toscanalifesciences.org/en/bioincubator/research-groups/center-for-immuno-oncology-university-hospital-of-siena/

      Dr. Michele Maio

      Dr. Michele Maio is full professor of Oncology at the University of Siena, Director of the Center for Immuno-Oncology, of the Division of Medical Oncology and Immunotherapy, and of the Department of Medical Oncology at the University Hospital of Siena, Italy. His clinical research interests include cancer immunobiology and epigenetics, as well as bioimmunotherapy of solid tumours. Dr. Maio is/has been Principal Investigator and National Coordinator of more than 100 Phase I‐III clinical trials.

      SOURCE iOnctura

      Modal title

      Also from this source

      Combinations of iOnctura's roginolisib revert immune suppression in immunotherapy-resistant NSCLC

      Combinations of iOnctura's roginolisib revert immune suppression in immunotherapy-resistant NSCLC

      iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today presented late-breaking data from...

      iOnctura to present late-breaking data on roginolisib in immunotherapy-resistant NSCLC at SITC

      iOnctura to present late-breaking data on roginolisib in immunotherapy-resistant NSCLC at SITC

      iOnctura today announced that a late-breaking poster evaluating roginolisib in patients with immunotherapy-resistant non-small cell lung cancer...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.